BNNC
BNNC is a Photomolecular glue. BNNC selectively releases (R)-CR8 (HY-18340) (a Cyclin K molecular glue) and BSS-Et in hypoxic tumor microenvironments, thereby triggering Cyclin K degradation dependent on the ubiquitin-proteasome pathway. BNNC generates ROS and singlet oxygen in hypoxic tumor cells under light irradiation. BNNC enhances DNA damage and Apoptosis through the combined effects of Cyclin K degradation and phototherapy. BNNC enhances the tumor selectivity of molecular glue via specific activation in hypoxic tumor microenvironments. BNNC can be used in breast cancer-related research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C72H70ClN13O6
- Masse moléculaire:1248.86
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
Description
In Vitro
BNNC (0-30 μM; 24 h) exhibits enhanced synergistic cytotoxicity against hypoxic 4T1 cells under 808 nm laser irradiation, reducing cell viability to less than 20% at a concentration of 30 μM, whereas it shows low cytotoxicity toward L02 hepatocytes at the same concentration[1].
BNNC (30 μM; 2 h) selectively induces ubiquitin-proteasome-dependent Cyclin K degradation in hypoxic 4T1 cells, but exerts no such effect in normoxic 4T1 cells[1].
BNNC (300 μg/mL RLM, 100 μM NADH; 40 min) exhibits stable and robust phototherapeutic functions and stability; after incubation with 300 μg/mL RLM for 40 min, it can fully respond to hypoxic environments to release (R)-CR8 and BSS-Et[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Mouse breast cancer 4T1 cells
-
Concentration:30 μM
-
Incubation Time:2 h
-
Result:Caused no change in Cyclin K protein levels under normoxic (21% O2) conditions.
Induced a marked reduction in Cyclin K protein levels under hypoxic (2% O2) conditions, comparable to free (R)-CR8.
Showed reversed Cyclin K degradation when pretreated with proteasome inhibitor MG132.
-
Cell Line:Mouse breast cancer 4T1 cells, human hepatocyte L02 cells
-
Concentration:0-30 μM
-
Incubation Time:24 h total; 2 h drug incubation prior to 5 min 808 nm laser irradiation
-
Result:Maintained >80% cell viability across all concentrations in normoxic (21% O2) dark conditions.
Showed concentration-dependent cytotoxicity comparable to BSS-Et under normoxic conditions with irradiation.
Exhibited enhanced concentration-dependent cytotoxicity in hypoxic (2% O2) dark conditions, similar to (R)-CR8.
Reduced hypoxic 4T1 cell viability to below 20% at 30 μM under irradiation.
Preserved >80% viability in L02 cells at 30 μM.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 7-8 weeks old, subcutaneous 4T1 breast cancer xenograft model)[1]
-
Dosage:30 μM (with 808 nm laser irradiation); 30 μM (without irradiation)
-
Administration:intratumorally; every other day; 21 days (7 cycles); 808 nm laser irradiation (1.5 W·cm-2, 10 min, 2 hours post each injection) for laser group
-
Result:Delayed tumor growth similarly to (R)-CR8 without irradiation.
Induced tumor growth arrest starting at day 12, culminating in overt tumor ablation with laser irradiation, with significantly greater efficacy than BSS-Et with laser irradiation, (R)-CR8, or BNNC without laser.
Marked Cyclin K depletion in BNNC-treated tumors confirmed via Western blot.
Showed greater γ-H2AX (DNA damage marker) levels in BNNC + laser tumors compared to single-agent groups.
Revealed minimal proliferative activity in BNNC + laser tumors via Ki67 immunohistochemistry.
Confirmed the most extensive apoptotic manifestations in BNNC + laser group via TUNEL and H&E staining.
Caused no appreciable body-weight loss.
Showed no morphological abnormalities, inflammatory infiltrates, or necrotic lesions in major organs (heart, liver, spleen, lung, kidney) via histopathological examination.
Chemical Information
-
Masse moléculaire 1248.86
-
Formule C72H70ClN13O6
-
SMILES
CC[C@H](COC(OCC(C=C1)=CC=C1/N=N/C(C=C2)=CC=C2COC(C(C=C3)=CC4=C3N(CC)/C(C4(C)C)=C\C=C5CCCC(/C=C/C(C(C)(C)O/6)=C(C#N)C6=C(C#N)\C#N)=C/5Cl)=O)=O)NC7=NC(N(C(C)C)C=N8)=C8C(NCC(C=C9)=CC=C9C%10=NC=CC=C%10)=N7
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BNNC Related Classifications
HY-184452 Related Classifications
Powered by Bioz